Bioventus Inc.(BVS)Stock Analysis

BVS Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Bioventus Inc. (BVS), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores BVS at 50.0/100 on a 32-signal composite quality model, placing it at rank #1,483 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include earnings quality (30.0) and revenue scale (38.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 39.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Bioventus Inc. reports quarterly revenue of $132.1M, net income of $3.1M, an operating margin of 6.4%. Top institutional holders of BVS by reported 13-F value include Essex Woodlands Management,, Juniper Investment Company,, Nantahala Capital Management,, based on the most recent SEC filings. BVS trades on the Nasdaq exchange and files with the SEC under CIK 1665988. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BVS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Bioventus Inc. directly from SEC EDGAR. Bioventus Inc.'s 13F Pro composite quality score has ranged between 8 and 50 since 2022, currently 50.0 — a stable long-term trajectory across 52 quarterly and live scoring snapshots.